


LABORATORIO PREGEN
Carrera 15a No 106-42
BOGOTA

Batch 2149, Rack A, Plate 1, Well B07, 173387
[9869A552F452C662] May 20, 2026 12:43:02

Pressure = 65 bar (65 to 66)

AF



PEAK	RT	REL	RT	% CONC	AREA	COMMENT
1	0.413	F	0.48	2.2%	11486	
2	0.500	F	0.59	2.7%	14080	
3	0.727	F	0.85	7.1%	36721	Acetylated F peak
4	0.858	F	1.01	25.5%	131349	Consistent with F
5	1.018	F	1.19	5.2%	26735	3
6	1.225	A	1.02	55.7%	286713	A peak - REVIEW
7	1.395	S	0.89	1.4%	7225	3
Total Area: 514309						

Codes: 1) Wide A peak
2) Area of A peak < 80%
3) Peak area greater than expected
4) Peak after A2
5) A1c > 10%
6) HbF or variant present
7) Total sample area too small/big
8) A2 is not within normal range

Dr. MARIA JOSE PINZON GARCIA
RED COLOMBIANA DE MEDICINA GENETICA SAS - PREGN
BOGOTA
CARRERA 15 A # 106 - 42
11001 BOGOTA
Colombia

Date of Report 29.05.2026
Sample Received 20.05.2026
Date of Sampling 12.05.2026
LAB-ID 262022204

Medical Report

Patient name	GUIZA MORENO MATHIAS	Sample-ID	A0340557
Date of Birth	21.02.2026	Gender	M

Indication: Newborn Screening

Method(s): Immunoassay, Tandem mass spectrometry from Dried Blood Spot. qPCR from Dried Blood Spot.

Results:

Parameter	Value	Unit	Reference
Birth weight (g)	3455	g	-
17-hydroxyprogesterone (17OHP)	<5.0	nmol/L	< 90.0
Thyroid-stimulating hormone (TSH)	1.7	μU/mL	< 15.0
Biotinidase	337.6	U	> 51.0
Galactose-1-P-uridyltransferase (GALT)	8.4	U/g Hb	> 2.5
Immunoreactive trypsinogen (IRT)	<15	ng/mL	< 65.0
Phenylalanine	37.3	μmol/L	< 150.0
Amino acid profile	negative		-
Acylcarnitine profile	negative		-

Interpretation: NEGATIVE RESULT

Contact Details

Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

Patient name	GUIZA MORENO MATHIAS
Date of Birth	21.02.2026

Sample-ID	A0340557
Gender	M

Results:

Amino Acids

Parameter	Value	Unit	Reference
Phenylalanine (Phe)	37.3	µmol/L	< 150.0
Phenylalanine / Tyrosine ratio (Phe/Tyr)	0.45	µmol/L	< 2.20
Tyrosine (Tyr)	82.6	µmol/L	< 200.0
Leucine (Leu)	136.7	µmol/L	< 270.0
Valine (Val)	77.4	µmol/L	< 200.0
Methionine (MET)	25.6	µmol/L	< 78.0
Methionine / Phenylalanine (Met/Phe)	0.69	µmol/L	< 1.60
Citrulline (Cit)	15.1	µmol/L	< 50.0
Ornithine (Orn)	68.9	µmol/L	< 250.0
Ornithine / Citrulline ratio (Orn/Cit)	4.56	µmol/L	1.50 - 20.00
Proline (Pro)	123.6	µmol/L	< 350.0
Alanine (Ala)	173.1	µmol/L	< 750.0
Arginine (Arg)	25.4	µmol/L	< 100.0
Aspartic acid (Asp)	64.8	µmol/L	< 100.0
Glutamic acid (Glu)	235.7	µmol/L	< 600.0
Glycamine (Gly)	147.2	µmol/L	< 700.0

Acylcarnitines

Free carnitine (C0)	46.25	µmol/L	6.00 - 100.00
acetylcarnitine (C2)	18.04	µmol/L	1.34 - 48.81
propionylcarnitine (C3)	1.85	µmol/L	0.13 - 6.60
butyryl-/isobutyrylcarnitine (C4)	0.15	µmol/L	0.03 - 0.90
isovaleryl-/2-methylbutyrylcarnitine(C5)	0.15	µmol/L	0.02 - 2.00
tiglylcarnitine (C5:1)	0.01	µmol/L	< 0.20
hydroxyvalerylcarnitine (C5OH)	0.39	µmol/L	0.02 - 0.57
glutaryl carnitine (C5DC)	0.04	µmol/L	< 0.30
hexanoylcarnitine (C6)	0.04	µmol/L	0.01 - 0.13
octanoylcarnitine (C8)	0.03	µmol/L	0.01 - 0.30
decanoylcarnitine (C10)	0.04	µmol/L	0.01 - 0.36
decenoylcarnitine (C10:1)	0.09	µmol/L	< 0.30
dodecanoylcarnitine (C12)	0.06	µmol/L	0.10 - 0.60
myristoylcarnitine (C14)	0.11	µmol/L	0.01 - 0.57
tetradecenoylcarnitine (C14:1)	0.11	µmol/L	0.10 - 0.38
palmitoylcarnitine (C16)	0.89	µmol/L	0.62 - 7.81
3-hydroxypalmitoylcarnitine (C16OH)	0.03	µmol/L	< 0.10
stearoylcarnitine (C18)	0.61	µmol/L	0.30 - 2.40
oleylcarnitine (C18:1)	4.08	µmol/L	0.06 - 3.86
3-hydroxystearoylcarnitine (C18OH)	0.01	µmol/L	< 0.09
malonylcarnitine (C3DC)	0.05	µmol/L	< 0.50

Amino acid levels are indicators of phenylketonuria, tyrosinemia, MSUD, hydroxyprolinuria, hypermethioninemia (homocystinuria), citrullinemia, argininosuccinate aziduria, hyperargininemia, and hyperprolinemia. Acylcarnitine levels are indicators of carnitine uptake disorders, CPT-I deficiency, CPT-II deficiency, CAT deficiency, propionaciduria, methylmalonic aciduria, malonic aciduria, SCAD deficiency/ethylmalonic aciduria, isovaleric aciduria, HMG-CoA lyase deficiency, 3-methylcrotonyl-CoA carboxylase deficiency, methylglutaconiduria, MCAD deficiency, VLCAD deficiency, LCHAD deficiency, glutaraziduria I, multiple acyl-CoA dehydrogenase deficiency (MAD deficiency/glutaraziduria II), and Beta-ketothiolase deficiency.

Please note: Inconspicuous negative biochemical results cannot exclude any inborn error of metabolism or endocrine disorder with certainty in newborns. We recommend any follow-up or genetic testing if any clinical symptoms are present.

Authorized By: Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
[Specialist for Pediatrics, Neonatology and Nutrition]

Report was electronically signed and approved.

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife GmbH
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria
www.archimedlife.com